



Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.  59 DIV US	SERIAL NO.  10/690,190
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)	APPLICANT:  Leonard Bell	
	FILING DATE  October 21, 2003	GROUP Art Unit:  <del>3736</del> 1644

## U.S. PATENT DOCUMENT

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>RV</i>	4 9 8 5 4 5 9	1/15/91	Sunshine et al.	—	—	
	5 6 3 5 1 7 8	6/03/97	Sims et al.	—	—	
	6 3 5 5 2 4 5	3/12/02	Evans et al.	—	—	

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
<i>RV</i>	9 5 2 5 5 4 0	9/28/95	WO	—	—		

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>RV</i>	Abdelmeguid et al., "Long-Term Outcome of Transient Uncomplicated In-Laboratory Coronary Artery Closure". Circulation, 1995:91:2733-2741
	Buerke et al., "Novel Small Molecule Inhibitor of C1s Exert Cardioprotective Effects in Ischemia-Reperfusion Injury in Rabbits", Journal of Immunology, 2001: Vol. 6, No. 9: 5375-5380.
	Calliff et al., "Myonecrosis After Revascularization Procedures", J. Amcoll Cardiol, 1998:31: 241-251.
	Fitch et al., "Pharmacology and Biological Efficacy of Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass", Circulation, 1999: Vol. 100, No. 25: 2502-2504.
	Gray et al., "Perioperative Myocardial Infarction: Late Clinical Course After Coronary Artery Bypass Surgery", Circulation, 1982: 66:1185-1189.
	Kong et al., "Prognostic Implication of Creatine Kinase Elevation Following Elective Coronary Artery Interventions", JAMA, 1997:277:461-466/
	Menasche, "The Systemic Factor: The Comparative Roles of Cardiopulmonary Bypass and Off-Pump Surgery in the Genesis of Patient Injury During and Following Cardiac Surgery", Annals of Thoracic Surgery, 2001: Vol. 6, No. 72: S2260-S2265,
	Thomas et al., "Inhibition of complement Activity by Humanized anti-C5 Antibody and Single-Chain Fv", Molecular Immunology, 1996, Vol. 33, No. 17/18, 1389-1401.
	Wurzner et al., "Inhibition of Terminal complement Complex formation and Cell Lysis by Monoclonal Antibodies", Complement Inflamm., 8:328-340, 1991.

EXAMINER

*[Signature]*

DATE CONSIDERED

2/14/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/690190
				Filing Date	October 21, 2003
				First Named Inventor	Leonard Bell
				Art Unit	1644
				Examiner Name	Nolan, Patrick J. VanderVest
Sheet	1	of	1	Attorney Docket Number	ALXN-P02-059

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
R	CJ	Bochanek et al., "Use of Cardiopulmonary Bypass Decreases Leukocyte Count and Activation of the Complement System," <i>Kardiologia Polska</i> 36(2):67-72 (English Abstract only)		
	CK	Gori et al., "Tissue Factor Reduction and Tissue Factor Pathway Inhibitor Release after Heparin Administration," <i>Thromb. Haemost.</i> 81:589-593 (1999)		
	CL	Wei et al., "Cytokine Responses and Myocardial Injury in Coronary Artery Bypass Grafting," <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> 61(2):161-166 (2001)		
	CM	Yilmaz et al., "Effect of Low-dose Methyl Prednisolone on Serum Cytokine Levels Following Extracorporeal Circulation," <i>Perfusion</i> 14(3):201-206 (1999)		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	2/14/06
--------------------	---	-----------------	---------